LYRA THERAPEUTICS INC by Lyra Therapeutics, Inc. Analyst Price Targets

Wall Street analyst price targets and consensus rating for LYRA THERAPEUTICS INC by Lyra Therapeutics, Inc. (LYRA).

Price Target Range — 6 Quarters

Analyst Consensus — 5 Analysts

2Buy

3Hold

Consensus RatingBuy# Analysts5Avg. Consensus PT$197Upside to Avg. PT+43677.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 14, 2025	HC Wainwright & Co.	Matthew Caufield	Maintained	Neutral	$16
Jun 10, 2025	HC Wainwright & Co.	Matthew Caufield	PT Raise	Neutral	$2→$16
Mar 14, 2025	HC Wainwright & Co.	Matthew Caufield	Maintained	Neutral	$2
Aug 15, 2024	Cantor Fitzgerald	Louise Chen	Maintained	Overweight	—
Aug 15, 2024	HC Wainwright & Co.	Matthew Caufield	Maintained	Neutral	$2
Jun 20, 2024	Cantor Fitzgerald	Louise Chen	Maintained	Overweight	—
May 7, 2024	HC Wainwright & Co.	Matthew Caufield	Downgrade	Buy→Neutral	$2
May 7, 2024	Jefferies	Dennis Ding	Downgrade	Buy→Hold	$10→$1
May 6, 2024	BTIG	Justin Zelin	Downgrade	Buy→Neutral	—
May 1, 2024	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$12
Mar 25, 2024	B of A Securities	Jason Gerberry	PT Cut	Buy	$12→$11
Mar 22, 2024	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$12

Benzinga Newsdesk

Benzinga Newsdesk

Rishabh Mishra

Benzinga Newsdesk

Benzinga Newsdesk

Benzinga Newsdesk